Corvus Pharmaceuticals (CRVS) Projected to Announce Quarterly Earnings on Tuesday

Corvus Pharmaceuticals (NASDAQ:CRVS) is expected to announce its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect Corvus Pharmaceuticals to announce earnings of ($0.1921) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 4:30 PM ET.

Corvus Pharmaceuticals (NASDAQ:CRVS) last announced its earnings results on Thursday, August 6th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.03). On average, analysts expect Corvus Pharmaceuticals to post ($0.79) EPS for the current fiscal year and ($1.06) EPS for the next fiscal year.

Corvus Pharmaceuticals Stock Performance

Shares of NASDAQ CRVS opened at $10.45 on Tuesday. Corvus Pharmaceuticals has a 12-month low of $6.39 and a 12-month high of $26.95. The firm has a 50 day moving average of $12.31 and a 200 day moving average of $14.28.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on CRVS. LADENBURG THALM/SH SH raised shares of Corvus Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, July 30th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Corvus Pharmaceuticals in a research report on Wednesday, September 16th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Corvus Pharmaceuticals in a report on Monday. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Corvus Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $33.33.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that harness the immune system to treat cancer. The company’s research centers on therapies designed to modulate immune-cell activity and address diseases with significant unmet medical needs.

Corvus’ leading product candidate is soquelitinib, formerly known as CPI-818, an oral, selective inhibitor of inducible T-cell kinase (ITK). The company is studying soquelitinib as a potential treatment for T-cell malignancies, including peripheral T-cell lymphoma.